Treats hypertension. ANDA 78232, held by Lupin. Losartan Potassium.
As of Nov 20, 2026, ANDA 78232 (Losartan Potassium), held by Lupin, was first approved by FDA on Oct 6, 2010, with 12 approved supplements and 0 published complete response letters.
Losartan potassium tablet USP is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 6, 2010 | Original application | Approved | None posted |
| Losartan Potassium25MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium50MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium100MG · tablet;oral | Losartan Potassium | Rx |
| Jun 8, 2026 | Supplement 44Labeling · Standard review | Approved | None posted |
| Aug 29, 2022 | Supplement 39Labeling · Standard review | Approved | None posted |
| Sep 30, 2020 | Supplement 30Labeling · Standard review | Approved | None posted |
| Nov 16, 2016 | Supplement 26Manufacturing | Approved | None posted |
| Jun 9, 2016 | Supplement 25Labeling · Standard review | Approved | None posted |
| Apr 15, 2015 | Supplement 2Labeling | Approved | None posted |
| Apr 15, 2015 | Supplement 23Labeling · Standard review | Approved | None posted |
| Sep 19, 2014 | Supplement 22Labeling · Standard review | Approved | None posted |
| Mar 26, 2014 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jan 28, 2013 | Supplement 16Labeling · Standard review | Approved | None posted |
| Dec 19, 2012 | Supplement 5Labeling | Approved | None posted |
| Dec 19, 2012 | Supplement 8Labeling | Approved | None posted |
| Oct 6, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters